Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma

Kunihiro Tsukasaki, Ambroise Marçais, Rihab Nasr, Koji Kato, Takahiro Fukuda, Olivier Hermine, Ali Bazarbachi

Research output: Contribution to journalReview article

Abstract

Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by human T-cell leukemia/lymphotropic virus type I (HTLV-1) endemic in some areas in the world. HTLV-1 transmits through mother-to-child infection via breastfeeding, sexual intercourses, and blood transfusions. Early HTLV-1 infection, presumably through mother’s milk, is crucial in developing ATL. The estimated cumulative risk of the development of ATL in HTLV-1 carriers is a few percent after transmission from their mothers. The median age of ATL onset is about 70 in Japan and is now rising, whereas an overall mean age in the mid-forties is reported in other parts of the world. ATL is classified into four clinical subtypes (acute, lymphoma, chronic, and smoldering) defined by organ lesions and LDH/calcium values. In aggressive ATL (acute, lymphoma or unfavorable chronic types) and indolent ATL (favorable chronic or smoldering types), intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation and watchful waiting until disease progression has been recommended, respectively, in Japan. Based on a worldwide meta-analysis and multiple other retrospective studies, the antiviral combination of interferon alpha (IFN) and zidovudine (AZT) is recommended in many parts of the world in acute, chronic, and smoldering ATL whereas patients with the lymphoma subtype are treated with chemotherapy, either alone or combined with AZT/IFN. Several new agents have been approved for ATL by the Pharmaceutical and Medical Devices Agency (PMDA) after clinical trials, including an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab; an immunomodulatory agent, lenalidomide; and an anti-CD30 antibody/drug conjugate, brentuximab vedotin.

Original languageEnglish
Article number1207
JournalFrontiers in Microbiology
Volume11
DOIs
Publication statusPublished - Jun 19 2020

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma'. Together they form a unique fingerprint.

  • Cite this